Lemtrada and T-lymphocyte count decreased - a phase IV clinical study of FDA data

Summary:

T-lymphocyte count decreased is reported as a side effect among people who take Lemtrada (alemtuzumab), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Ocrevus, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have T-lymphocyte count decreased when taking Lemtrada. It is created by eHealthMe based on reports of 8,297 people who have side effects when taking Lemtrada from the FDA, and is updated regularly.

What is Lemtrada?

Lemtrada has active ingredients of alemtuzumab. eHealthMe is studying from 8,317 Lemtrada users. Check the latest studies of Lemtrada.

What is T-lymphocyte count decreased?

T-lymphocyte count decreased is found to be associated with 116 drugs and 201 conditions by eHealthMe. Check the latest studies of T-lymphocyte count decreased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

8,297 people reported to have side effects when taking Lemtrada.
Among them, 24 people (0.29%) have T-lymphocyte count decreased.

Could Lemtrada cause T-lymphocyte count decreased?

Among these 24 people:

How long have people been on Lemtrada when they have T-lymphocyte count decreased? *

What is the gender of people who have T-lymphocyte count decreased when taking Lemtrada? *

female: 90.48 %
male: 9.52 %

What is the age of people who have T-lymphocyte count decreased when taking Lemtrada? *

What are other drugs people take besides Lemtrada? *

What are other side effects people have besides T-lymphocyte count decreased? *

Urinary Tract Infection: 10 people, 41.67%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 10 people, 41.67%
Fatigue (feeling of tiredness): 9 people, 37.50%
Cd4 Lymphocytes Decreased: 9 people, 37.50%
B-Lymphocyte Count Decreased: 9 people, 37.50%
Gait Disturbance: 8 people, 33.33%
B-Lymphocyte Count Increased: 8 people, 33.33%
Back Pain: 8 people, 33.33%
Weakness: 8 people, 33.33%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 7 people, 29.17%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 10 people, 41.67%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 7 people, 29.17%
Urinary Retention (the inability to completely or partially empty the bladder): 3 people, 12.50%
Rickets (softening of bones): 3 people, 12.50%
Neuralgia (pain in one or more nerves): 3 people, 12.50%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 3 people, 12.50%
Fatigue (feeling of tiredness): 3 people, 12.50%
Migraine (headache): 2 people, 8.33%
Anogenital Warts: 2 people, 8.33%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Lemtrada and have T-lymphocyte count decreased?

- Check whether T-lymphocyte count decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lemtrada:

Lemtrada (8,317 reports)

Browse all side effects of Lemtrada:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with T-lymphocyte count decreased:

T-lymphocyte count decreased (116 drugs)

Browse all the conditions that are associated with T-lymphocyte count decreased:

T-lymphocyte count decreased (201 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Lemtrada) and Lemtrada (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.